Psoriasis Area and Severity Index vs. pharmacokinetics: can monitoring 4-week postinjection ustekinumab concentrations in patients with suboptimal response be clinically relevant?

Psoriasis Area and Severity Index vs. pharmacokinetics: can monitoring 4-week postinjection ustekinumab concentrations in patients with suboptimal response be clinically relevant? Br J Dermatol. 2019 Dec 11;: Authors: Puig L PMID: 31828758 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/31828758?dopt=Abstract

Source: The British Journal of Dermatology - December 10, 2019 Category: Dermatology Authors: Puig L Tags: Br J Dermatol Source Type: research

More News: Dermatology | Psoriasis | Skin | Stelara | UK Health